Raptinal Induces Gasdermin E-Dependent Pyroptosis in Naïve and Therapy-Resistant Melanoma

Area of Science:

• Oncology
• Cell Biology
• Immunology

Background:

• Targeted and immune-based therapies for melanoma face limitations due to lack of response and acquired resistance.
• Pyroptosis, an inflammatory cell death, involves gasdermin (GSDM) pores releasing damage-associated molecular patterns (DAMPs) and cytokines.
• Inducing pyroptosis offers potential therapeutic strategies for both responsive and resistant melanoma.

Purpose of the Study:

• To investigate the potential of raptinal, a caspase-3 activator, in inducing pyroptosis in melanoma.
• To evaluate raptinal's efficacy in both therapy-naïve and treatment-resistant melanoma models.
• To assess the role of caspase activity and GSDME expression in raptinal-induced pyroptosis.

Main Methods:

• Utilized human and mouse melanoma cell line models.
• Administered raptinal to induce pyroptosis.
• Assessed tumor growth delay in vivo.
• Measured release of DAMPs and inflammatory cytokines.
• Investigated pyroptosis induction in melanoma models resistant to BRAF and MEK inhibitors.

Main Results:

• Raptinal effectively induced pyroptosis in both human and mouse melanoma cell lines.
• Raptinal treatment led to a delay in tumor growth in vivo.
• The release of DAMPs and cytokines was dependent on caspase activity and GSDME expression.
• Raptinal induced pyroptosis in melanoma models that had acquired resistance to BRAF and MEK inhibitor therapy.

Conclusions:

• Raptinal is a potent inducer of pyroptosis in melanoma, applicable to both treatment-naïve and resistant settings.
• The findings support the therapeutic potential of inducing pyroptosis to overcome resistance to targeted therapies in melanoma.
• Raptinal's ability to induce pyroptosis in resistant melanoma offers a promising avenue for future treatment strategies.